Literature DB >> 18425105

Natural killer cell-directed therapies: moving from unexpected results to successful strategies.

Magali Terme1, Evelyn Ullrich, Nicolas F Delahaye, Nathalie Chaput, Laurence Zitvogel.   

Abstract

Natural killer (NK) cells influence innate and adaptive immune host defenses. Existing data indicate that manipulating the balance between inhibitory and activating NK receptor signals, the sensitivity of target cells to NK cell-mediated apoptosis, and NK cell cross-talk with dendritic cells might hold therapeutic promise. Efforts to modulate NK cell trafficking into inflamed tissues and/or lymph nodes, and to counteract NK cell suppressors, might also prove fruitful in the clinic. However, deeper investigation into the benefits of combination therapy, greater understanding of the functional distinctions between NK cell subsets, and design of new tools to monitor NK cell activity are needed to strengthen our ability to harness the power of NK cells for therapeutic aims.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18425105     DOI: 10.1038/ni1580

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  120 in total

1.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

2.  hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.

Authors:  Wen Jiang; Cai Zhang; Zhigang Tian; Jian Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-08       Impact factor: 4.553

3.  Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo.

Authors:  Weijuan Gong; Weiming Xiao; Li Qian; Chunxiang Gong; Maozhi Hu; Xianyuan Pan; Mingchun Ji
Journal:  Cell Mol Immunol       Date:  2010-09-27       Impact factor: 11.530

Review 4.  Natural killer cells in immunodefense against infective agents.

Authors:  Nicolas Zucchini; Karine Crozat; Thomas Baranek; Scott H Robbins; Marcus Altfeld; Marc Dalod
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

Review 5.  Dendritic cell interactions with NK cells from different tissues.

Authors:  Guido Ferlazzo; Christian Münz
Journal:  J Clin Immunol       Date:  2009-03-12       Impact factor: 8.317

Review 6.  Inflammation-on-a-Chip: Probing the Immune System Ex Vivo.

Authors:  Daniel Irimia; Xiao Wang
Journal:  Trends Biotechnol       Date:  2018-05-01       Impact factor: 19.536

7.  Adoptively transferred natural killer cells maintain long-term antitumor activity by epigenetic imprinting and CD4+ T cell help.

Authors:  Jing Ni; Oliver Hölsken; Matthias Miller; Quirin Hammer; Merlin Luetke-Eversloh; Chiara Romagnani; Adelheid Cerwenka
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

8.  Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis.

Authors:  Stacy J Park; Molly A Hughes; Marie Burdick; Robert M Strieter; Borna Mehrad
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

9.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16

10.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.

Authors:  Natalia Lapteva; April G Durett; Jiali Sun; Lisa A Rollins; Leslie L Huye; Jian Fang; Varada Dandekar; Zhuyong Mei; Kimberley Jackson; Juan Vera; Jun Ando; Minhtran C Ngo; Elaine Coustan-Smith; Dario Campana; Susann Szmania; Tarun Garg; Amberly Moreno-Bost; Frits Vanrhee; Adrian P Gee; Cliona M Rooney
Journal:  Cytotherapy       Date:  2012-08-17       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.